ERR2208939
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- HEDGEHOG_SIGNALING+0.400
- MYOGENESIS+0.400
- TGF_BETA_SIGNALING+0.400
- ANDROGEN_RESPONSE+0.300
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- COAGULATION+0.300
- HYPOXIA+0.300
- MITOTIC_SPINDLE+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- ALLOGRAFT_REJECTION-0.200
- MYC_TARGETS_V2-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- ADIPOGENESIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- KRAS_SIGNALING_DN-0.100
- P53_PATHWAY-0.100
- BILE_ACID_METABOLISM+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A152-01A-11R-A12D-07 | — | C | 0.791 |
| 2 | TCGA-UY-A8OC-01A-11R-A36F-07 | — | — | 0.776 |
| 3 | TCGA-77-7338-01A-11R-2045-07 | — | cohortSQ2 | 0.774 |
| 4 | SRR8943050 | — | — | 0.761 |
| 5 | R211 | — | — | 0.758 |
| 6 | SRR25617936 | — | E | 0.757 |
| 7 | SRR17866829 | — | — | 0.733 |
| 8 | TCGA-44-8119-01A-11R-2241-07 | — | cohortA3 | 0.730 |
| 9 | SRR8518155 | — | E | 0.730 |
| 10 | TCGA-AN-A0AS-01A-11R-A00Z-07 | — | C | 0.729 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |